Caliper Unit Xenogen Pens Target Validation Deal With Schering-Plough
 
Caliper Life Sciences business unit Xenogen Biosciences will collaborate with Schering-Plough Research Institute to validate targets in drug discovery, Xenogen said this week.
 
Xenogen will use its serial phenotyping compression technology to characterize high-value targets, it said. The technology relies on a battery of more than 85 pharmacologically validated bioassays.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.